Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged \textit{PDGFRB} genes

Hung Chang\textsuperscript{1,2,*}, Wen-Yu Chuang\textsuperscript{1,3}, Chien-Feng Sun\textsuperscript{1,3} and Marc R Barnard\textsuperscript{4}

\textbf{Abstract}

Concurrent hematologic malignancies are relatively rare. We encountered a case of concurrent acute myeloid leukemia (AML) and T lymphoblastic lymphoma. The bone marrow chromosome analysis showed the karyotype 46, XY, t(5;12) (q33;p13), which indicated presence of \textit{PDGFRB} gene translocations. Therefore, this disease belongs to the new WHO category of myeloid and lymphoid neoplasms with abnormalities in \textit{PDGFRB} genes. Although such genetic mutations are prone to multi-lineage differentiation, the present case is in fact the first report of concurrent AML and T lymphoblastic lymphoma involving \textit{PDGFRB} mutations. The patient was treated with cytarabine and daunomycin in combination with high dose dexamethasone. Allogeneic stem cell transplantation was performed after successful remission induction for both entities. The patient eventually died of chronic graft-versus-host-disease related infection. Based on such an experience, we suggest the decision of stem cell transplantation should be weighed carefully against the risks, especially when tyrosine kinase inhibitors are safe and potentially effective in dealing with such entities.

\textbf{Keywords:} Acute myeloid leukemia, T lymphoblastic lymphoma, \textit{PDGFR} genes, Chromosomal translocation, Transplantation

\textbf{Background}

In 2008, a new class of hematopoietic system disorders, myeloid and lymphoid neoplasms with eosinophilia and abnormalities in \textit{PDGFRB}, \textit{PDGFRB} and \textit{FGFR1} genes, was created by WHO \cite{1}. Although most cases presented with myeloproliferative neoplasm (MPN) and eosinophilia, this group of diseases was known to develop into multiple lineages of hematologic malignancies both in animal models and human cases \cite{2}. In humans, concurrent myeloid neoplasms and T lymphoblastic lymphoma have been reported with \textit{FIP1L1-PDGFR} fusion genes \cite{3,4} but not with any \textit{PDGFRB} rearranged genes. Neoplastic cells bearing such mutations are susceptible to tyrosine kinase inhibitors and successful treatment experiences have been reported \cite{5-9}.

\textbf{Case presentation}

A 41-year-old businessman presented with multiple subcutaneous nodules in the arms and trunk 3 weeks before admission. These nodules were rapidly enlarging but neither painful nor pruritic. He also reported several systemic symptoms including malaise, drenching night sweat and generalized arthralgia. His urine amount decreased markedly and he gained 3 kilograms before admission. At admission, subcutaneous nodules were found in his arms, trunk and thighs. Enlarged lymph nodes that were fixed, discrete and elastic were palpated in neck, axillary, and inguinal areas. Liver and spleen were not palpable. Marked general edema was observed. Other physical findings were unremarkable. A complete blood count revealed a hemoglobin level 10.9 g/L, a platelet count $53 \times 10^9/L$, a white cell count $70.7 \times 10^9/L$ with 20% blasts, 3% promyelocytes, 7.5% myelocytes, 3% metamyelocytes, 31% neutrophils, 0.5% eosinopils, 24.3% monocytes and 10.8% lymphocytes. The liver biochemistry profiles were normal but the renal function tests showed creatinine 2.21 mg/dL, uric acid 15.5 mg/dL, lactate dehydrogenase 612 U/L, calcium 9.1 mg/dL, and phosphate 2.4 mg/dL. Under the impression of spontaneous tumor lysis syndrome, he was treated with hydration and rasburicase 0.15 mg/kilogram. His renal
function and edema improved gradually. Meanwhile, a biopsy of the right inguinal lymph node was done. The sections showed fragments of lymphoid tissue with diffuse infiltrates of medium-sized lymphoid cells, which had fine chromatin and small nucleoli (Figure 1A). The tumor cells were positive for CD3 (Figure 1B), CD5 and TIA-1. A part of them were also positive for TdT (Figure 1C). They were negative for CD20, cyclin D1, myeloperoxidase (Figure 1D), CD4, CD8, CD30, CD56 and CD25. About 95% of the tumor cells were positive Ki-67. It was classified as T lymphoblastic lymphoma.

The bone marrow aspiration smear and biopsy revealed hypercellular bone marrow with myeloblasts accounting for 36.7% of nucleated cells (Figure 2A). All leukemic cells were positive for peroxidase (Figure 2B). A flow cytometric analysis revealed the leukemic cells were positive for CD13, CD33, CD14, CD15, CD65 and negative for CD34, CD117, CD56, CD7 and CD19. In addition, the immunohistochemical stain of the bone marrow tissue section showed the blast cells were strongly positive for myeloperoxidase but negative for TdT, CD10, CD2, CD5 and CD20. The diagnosis of AML was established. The chromosome analysis revealed the karyotype 46, XY, t(5;12)(q33;p13). There was no detectable AML1-ETO, CBFb-MYH11, or MLL-PTD fusion transcripts shown by reverse transcriptase polymerase chain reactions. A fluorescent in situ hybridization (FISH) analysis with dual color PDGFRB probes was performed on patient’s BM sample. It was positive for PDGFRB translocations.

He received induction chemotherapy with cytarabine (100 mg/m²/day continuous infusion for 7 days) and daunomycin (50/m²/day for 3 days). Dexamethasone 20 mg/day in divided doses was given in the same time, tapered off in a month. He had complete regression of lymph nodes and skin lesions and complete remission of AML. He subsequently received 2 cycles of postremission chemotherapy (cycle 1: cytarabine 3 g/m² for

---

**Figure 1** Histology of the lymph node biopsy. **A**. diffuse infiltrates of medium-sized lymphoid cells, which had fine chromatin and small nucleoli. **B**. tumor cells positive for CD3 (Polyclonal). **C**. a part of tumor cells positive for TdT. **D**. tumor cells were negative for myeloperoxidase (Polyclonal).
6 doses; cycle 2: cytarabine 1 g/m² for 6 doses and eto-
poside 100 mg/m²/day for 3 days). In the state of con-
tinued remission, he underwent allogeneic stem cell
transplantation from an HLA-matched sibling donor.
Eleven months after transplantation, he died of chronic
graft versus host disease (GVHD) and related pulmonary
infection.

Discussion
Concurrent myeloid and lymphoid malignancies are quite
uncommon. The difficulty of diagnosis can be illustrated
in the present case. At presentation, generalized subcuta-
neous tumors and lymphadenopaties led to the diagnosis
of a high grade lymphoma. The pathological diagnosis of
T lymphoblastic lymphoma was made unequivocally by
typical morphology and detailed immunophenotypical stu-
dies. The clinical course was complicated with sponta-
neous tumor lysis syndrome, which typically occurred in
high grade lymphoma and therefore supported the diagno-
sis of T lymphoblastic lymphoma. Although lymphoblastic
lymphoma may involve bone marrow or peripheral blood,
the results of bone marrow studies revealed the leukemic
cells did not belong to the T-lineage. The strongly positive
myeloperoxidase staining suggested the diagnosis of AML.
This was further confirmed definitively by its typical
immunophenotypical profile. Some leukemic cells of AML
may occasionally express T cell markers. In our case, how-
ever, the leukemia cells was found negative for CD2, CD5
and CD7, making aberrant expression of AML relatively
unlikely. The diagnosis of concomitant AML and T lymph-
obllastic lymphoma, was confirmed.

Although it appears unusual, such concurrence is not
coincidental. In English literature, similar cases have been
reported. In 2007, Metzgerot et al. reported 7 cases of
AML or T lymphoblastic lymphoma bearing FIP1L1-
PDGFA fusion genes. In 2 cases, T lymphoblastic lym-
phoma was found synchronously with myeloid neoplasms
(acute eosinophilic leukemia in one and MPN in the
other) [4]. In 2008, Capovilla et al. reported another case
of synchronous chronic eosinophilic leukemia and T
lymphoblastic lymphoma. Like the previous report, the
leukemic cells were found to bear FIP1L1-PDGFRA fusion
genes [3]. It appears from these reports that such genetic
aberrations may lead to mixed lineage differentiation. In
contrast to the previous reports with PDGFA gene rear-
rangements, the present case was found to bear t(5;12)
(q33;p13). This translocation most likely involves PDGFRB
genes mapped on chromosome 5p. This assumption was
further confirmed by studies of FISH. Based on chromosom-
also mapping and prior literature reports, the most likely
partner gene is ETV6 [10].

In 2008 WHO classification, a new class of hemato-
poietic diseases, myeloid and lymphoid neoplasms with
eosinophilia and abnormalities in PDGFRα, PDGFRB and
FGFR1 genes, were introduced [1]. In such a classifica-
tion system, all cases of concurrent myeloid neoplasms
and T lymphoblastic lymphoma, including the present
case, belong to the same category. While most cases of
this entity presented with MPNs, the genetic aberrations
have a wide spectrum of differentiations, including eosin-
ophilia, myelodysplastic syndrome, chronic myelomo-
nocytic leukemia, AML, B or T cell acute lymphoblastic
leukemia, T lymphoblastic lymphoma, and disorders with
mast cell proliferation [2]. Most cases with PDGFRα
gene rearrangements manifest as MPNs, usually chronic
eosinophilic leukemia. PDGFRB gene rearrangement
cases typically present as MPNs which are almost always
accompanied with eosinophilia. Aberrations of FGFR1
genes are also commonly associated with MPNs with
eosinophilia. In particular, this genetic mutation is often
associated with differentiation into both myeloid and
lymphoid lineages. The most common lymphoid neo-
plasm is T lymphoblastic lymphoma. The concurrence of
myeloid and lymphoid malignancies was reported both in
human cases and animal models [2].

While these reports revealed it is not uncommon for
PDGFRα and FGFR1 genetically rearranged cells to differ-
entiate into lymphoid neoplasms, hematologic diseases
bearing PDGFRB mutations are rare [2,5]. The two largest
series reported in literature included 22 and 9 cases

![Figure 2 Bone marrow aspiration smear. A. myeloblasts accounting for 36.7% of nucleated cells. B. all leukemic cells positive for peroxidase.](image-url)
respectively. PDGFRB rearranged cells are known to develop into B and T lineage lymphoma [2]. This differentiation pattern was well described in transgenic mice models [11,12]. However, according to an extensive review by Holroyd et al, patients with PDGFRB mutations have not been known to develop lymphoid malignancies. This is somewhat surprising and may be explained by the rarity of such mutations among humans [2]. As a result, the case in the present article is the first case report of lymphoma and concurrent AML bearing PDGFRB gene mutations.

Treatment of concurrent AML and T lymphoblastic lymphoma and AML is a clinical challenge. There is mounting evidence that PDGFRα, PDGFRB and FGFR1 entities respond well to tyrosine kinase inhibitors [2,5,9,10,13]. However, tyrosine kinase inhibitors are expensive and still off-label for lymphoma. Therefore, we did not consider tyrosine kinase inhibitors as the frontline treatment in this case. In view of the simultaneous expression of myeloid and lymphoid lineage features, consideration of chemotherapeutic regimens is similar to that of bi-phenotypic leukemia. Bi-phenotypic leukemia is an uncommon disorder. No consensus protocol is available for treatment. Some studies suggest that bi-phenotypic leukemia has good responses to treatment directed against AML [14-16]. As a result, we chose treatment that was based on cytarabine and daunomycin. Steroids were included in the induction phase and complete remission was achieved for both AML and lymphoma. The patient subsequently underwent sibling-matched, allogeneic stem cell transplantation, which was quite successful until the development of chronic GVHD. Although the patient died of GVHD and related infections, he remained free from both malignancies for at least 11 months after transplantation. We believe allogeneic stem cell transplantation is an effective, albeit risky treatment option. Clinicians should weigh the risk against potential benefits before deciding treatment strategies, especially when tyrosine kinase inhibitors have become relatively safe and effective options.

Consent
Some of the laboratory and genetic testing included in this study was done by surplus clinical samples. An informed consent to utilize the samples was available for review. The consent form was approved by the institutional review board in Chang Gung Memorial Hospital.

Acknowledgements
This work was supported by grant DHR99-TD-C-111-006 from the Department of Health, Executive Yuan, Taiwan.

Author details
1 School of Medicine, Chang Gung University, Taoyuan, Taiwan. 2 Division of Hematology-Oncology Chang Gung Memorial Hospital, 5 Fu-Shing Street, Kweishan, Taoyuan 333, Taiwan. 3 Department of Pathology, Chang Gung Memorial Hospital, Taipei, Taiwan. 4 Core Flow Cytometry Laboratory, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.

Authors’ contributions
HC wrote this manuscript. WYC and CFS conducted the pathology interpretation and drafted the related parts in the article. MRB revised the article. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 31 December 2011 Accepted: 22 February 2012

Published: 22 February 2012

References
1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
2. Holroyd A, Cross NC, Macdonald DH: The two faces of myeloproliferative neoplasms: molecular events underlying lymphoid transformation. Leuk Res 2011, 35:1279-1285.
3. Capovilla M, Cayuela JM, Bilhau-Nabera C, Gardin C, Leteurtre P, Baran-Mazak F, Penaux P, Martin A: Synchronous FIP1L1-PDGFRα-positive chronic eosinophilic leukemia and t-cell lymphoblastic lymphoma: a bimodal clonal malignancy. Eur J Haematol 2008, 80:81-86.
4. Metzgeroth G, Walz C, Colour J, Siebert R, Schnitter S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Muller MC, Beneke H, Muller L, Del Valle F, Auilotoke W, Wiltowskoy G, Schmitz N, Schulte C, Muller-Hermelink K, Hodges E, Whitaker SJ, Decker F, Dohner H, Schulte P, Hohlmann R, Hochhaus A, Cross NC, Reiter A: Recurrent finding of the FIP1L1-PDGFRα fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic t-cell lymphoma. Leukemia 2007, 21:1183-1188.
5. Apperley JF, Gardembas M, Molfo JV, Russell-Jones R, Ban B, Baker EJ, Chase A, Chellsell JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schulteis B, Cross NC, Goldman JM: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
6. Eilng C, Erben P, Walz C, Frickehaus M, Schemionek M, Stehling M, Serve H, Cross NC, Hochhaus A, Hoffmann WK, Bredel WE, Muller-Tidow C, Reiter A, Koschmieder S: Novel imatinib-sensitive PDGFRα-activating point mutations in hyperesinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011, 117:2935-2943.
7. Helbig G, Moraska A, Huis M, Piszcz J, Swiderska A, Urbanowicz A, Calbieda M, Seferynska I, Razny M, Rodzaj M, Zek E, Kyrcz-Krznien S: Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukemia. Cancer Chemother Pharmacol 2011, 67:967-969.
8. Rathe M, Kristensen TK, Moller MB, Carlsten NL: Myeloid neoplasm with prominent eosinophilia and pdgfrα rearrangement treated with imatinib mesylate. Pediatr Blood Cancer 2010, 55:730-732.
9. Walz C, Erben P, Ritter M, Noor A, Schettgen G, Telford N, Haferlach C, Haferlach T, Gesk S, Stoeckle J, Hoffmann WK, Hochhaus A, Cross NC, Reiter A: Response of ETV6-FIL1-positve myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 2011, 118:2239-2242.
10. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor beta to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with 15(12) chromosomal translocation. Cell 1994, 77:507-516.
11. Tomasson MH, Williams IR, Hasserjian R, Udomsakdi C, McGrath SM, Schwaller J, Duker B, Gilliland DG: TEL-PDGFBetα fusion gene produces a chronic myeloproliferative syndrome in transgenic mice. Leukemia 1999, 13:1790-1803.
13. Shin J, Kim M, Kim DB, Yeom JO, Lee HJ, Cho SG: Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13). Acta Haematol 2008, 119:57-59.

14. Serefhanoglu S, Boyukasik Y, Goker H, Sayinalp N, Ozcebe OI: Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series. J Natl Med Assoc 2009, 101:270-272.

15. Zhang J, Mi YC, Wang Y, Lin D, Li W, Sun XM, Zhou K, Bao SG, Wang JX: study on the clinical characteristics of adult biphenotypic acute leukaemia. Zhonghua XueYeXueZa Zhi 2009, 30:18-21.

16. Zheng C, Wu J, Liu X, Ding K, Cai X, Zhu W: What is the optimal treatment for biphenotypic acute leukemia? Blood 2009, 94:1778-1780.

doi:10.1186/1746-1596-7-19
Cite this article as: Chang et al: Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes. Diagnostic Pathology 2012 7:19.